Home › Funds › BAKER BROS. ADVISORS LP › AKTS
BAKER BROS. ADVISORS LP position in AKTS
AKTIS ONCOLOGY INC · Health Care
BAKER BROS. ADVISORS LP reported holding 996,351 shares of AKTS (AKTIS ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$32.1M, representing 0.17% of its reported portfolio and ranking #44 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's AKTS position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in AKTS in Q1 2026 at 996,351 shares (US$17.8M). The position peaked in Q2 2026 at 996,351 shares, worth US$32.1M. Across 2 filings, BAKER BROS. ADVISORS LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 996,351 shares valued at US$32.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 996.35K | $17.82M | New |
| Q2 2026 | 996.35K | $32.11M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AKTS and 13F data
AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 121 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AKTS
- MPM BioImpact LLC 4.84M sh · $155.86M · Q2 2026
- EcoR1 Capital, LLC 4.82M sh · $155.49M · Q2 2026
- Blue Owl Capital Holdings LP 3.07M sh · $98.95M · Q2 2026
- RTW INVESTMENTS, LP 1.59M sh · $51.31M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.31M sh · $42.36M · Q2 2026
- Octagon Capital Advisors LP 960.85K sh · $30.97M · Q2 2026
- Merck & Co., Inc. 952.84K sh · $30.71M · Q2 2026
- TCG Crossover Management, LLC 696.56K sh · $22.45M · Q2 2026
- Avidity Partners Management LP 484.20K sh · $15.61M · Q2 2026
- a16z Capital Management, L.L.C. 415.00K sh · $13.38M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held AKTS?
BAKER BROS. ADVISORS LP has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is BAKER BROS. ADVISORS LP's current position in AKTS?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 996.35K shares of AKTS (AKTIS ONCOLOGY INC), valued at $32.11M, representing 0.17% of its reported portfolio and ranking #44.
Has BAKER BROS. ADVISORS LP been buying or selling AKTS?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in AKTS. The position peaked in Q2 2026 at 996.35K shares.
Which other funds hold AKTS?
Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 121 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.